Combined oestrogen and progestin HRT increases the risk to 2.7%, but oestrogen-only HRT decreases it to 1.9%. In other words, 80% of women who use HRT after medium-risk breast cancer will not experience a relapse. For women with low-risk breast cancer, HRT increases the risk of relapse from 5% to 7.2%. Crucially, most of the increase in risk from use of HRT is from local relapse or a second breast cancer which, while serious, are usually fully treatable. For example, HRT increases the 7-year distant relapse rate from 5.8% to 6.3% in women with moderate-risk breast cancer, and from 2.1% to 2.3% in women with low-risk disease.